Business briefs: Merck, AbbVie, Roche, plus new FDA device rule
September 23, 2013
5:36 pm
Complete Response letter slows Merck’s suggamedex; AbbVie looks for next Humira; Roche drug gets breakthrough label; FDA effort to better track medical devices
Business briefs: Gilead, Boehringer, Rx sample ban
September 19, 2013
4:25 pm
Gilead’s Striblid faces hurdle in Germany, Boehringer and Roche team up for companion diagnostic effort and Wisconsin hospital system says no to samples
Business briefs: Boehringer Ingelheim, Sanofi, GSK, Teva
September 17, 2013
6:40 pm
BI cancer drug lands breakthrough therapy designation; Sanofi tallies two European MS drug approvals; GSK terminates testing for a Crohn’s drug; and Teva joins cancer collaboration
Business briefs: GSK, Roche, Biogen Idec, Forest
September 10, 2013
4:44 pm
FDA draft guidance for generic Advair hits GSK’s stock; US looks into GSK’s China conduct; Roche invests in cancer and hep. B research; Biogen inks a Parkinson’s partnership; Forest names former B&L chief as CEO
Business briefs: Bristol-Myers Squibb, Zafgen, GSK, Shire
August 26, 2013
5:43 pm
Australia’s price watchdogs are assessing the value of BMS cancer drug Yervoy; why a Phase II weight drug from Zafgen could open up the category; GSK halts a Crohn’s trial; and Shire extends Santaris rare-disease collaboration
Business briefs: Sanofi, Celgene, plus changing cancer definitions
July 30, 2013
6:24 pm
Sanofi may make OTC history; Celgene joins a new collaboration; and the US Task Force of Preventative Medicine wants to make lung cancer screening the norm
Business briefs: Amgen and Wockhardt
July 10, 2013
4:55 pm
Amgen pays $50 million for a cardio collaboration, and Wockhardt gets locked out of the EU.
Business briefs: Astellas, ADA, AJMC, AARP
June 25, 2013
4:25 pm
Astellas teams up with Cytokinetics for muscle weakness research; ADA says lifestyle changes don’t protect diabetics’ hearts; AJMC talks pharmacists as diabetes counselors; and AARP helps with healthcare reform education.
Merck throws more staff behind Januvia; overall sales slid for quarter